Screener
CG Oncology CGON Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by CG Oncology in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: CG Oncology’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 8:45 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336918
FAQ
- What is CG Oncology's retained earnings?
- CG Oncology (CGON) reported retained earnings of -$518.23M in Q2 2026.
- How has CG Oncology's retained earnings changed year-over-year?
- CG Oncology's retained earnings decreased by 76.4% year-over-year, from -$293.86M to -$518.23M.
- What is the long-term trend for CG Oncology's retained earnings?
- Over 2 years (2023 to 2025), CG Oncology's retained earnings has grown at a 70.8% compound annual growth rate (CAGR), from -$129.94M to -$378.98M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about CG Oncology's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude